Loading stock data…
TXG
$22.01+0.36 (+1.66%)
Pre-Market$22.39+0.38 (+1.73%)· Last close May 5
10x Genomics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
10x Genomics, Inc. in the Healthcare sector is trading at $22.01. The stock is currently 17% below its 52-week high of $26.45, remaining 29.2% above its 200-day moving average. Technical signals show neutral RSI of 36 and bearish MACD signal, explaining why TXG maintains its current momentum and trend strength. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 36) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$22.01
Potential Upside
5%
Whystock Fair Value$23.11
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Buy
Mean target$24.00+9.0%
Range$17.00 – $32.00
Fundamentals
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.92B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.17
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-10.62%
Volume
Today's trading volume
2.66M
Recent News
Should Launch of Atera Spatial Biology Platform Require Action From 10x Genomics (TXG) Investors?
In April 2026, 10x Genomics launched Atera, an in situ spatial biology platform unveiled at AACR that offers whole-transcriptome, single-cell–sensitive spatial analysis across fresh-frozen and FFPE tissues, supported by a new cloud analysis suite and pre-order availability ahead of shipments expected in the second half of 2026. Early adoption commitments from major research consortia, global CROs like Macrogen, and AI-focused partners suggest Atera could materially broaden how 10x Genomics’...
10x Genomics (TXG) Expected to Beat Earnings Estimates: Should You Buy?
10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 Unprofitable Stock to Target This Week and 2 That Underwhelm
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
Tempus AI Stock Before Q1 Earnings Release: To Buy or Not to Buy?
TEM faces pressure ahead of Q1 earnings as macro headwinds, high valuation and estimate trends cloud its near-term investment appeal.
1 Cash-Heavy Stock to Target This Week and 2 We Ignore
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.